COVID-19, Frailty, Mortality
Conditions
Brief summary
Covid-19 patients admitted to the intensive care unit of Selcuk University Hospital were included in the study. Clinical frailty score was given during admission to the intensive care unit. Demographic data, laboratory data, radiological imaging and vital signs of the patients were recorded. Treatment and patient positions were recorded during the intensive care follow-up of the patients. Mortality status of the patients 6 months after admission to the ICU was recorded.
Detailed description
It is planned to include non-pregnant and non-traumatic patients over the age of 18, diagnosed with COVID-19, who are treated in the Intensive Care Unit of Selcuk University Hospital. The frailty status will be evaluated by using the clinical frailty scale at the admission of the patients to the intensive care unit. Evaluation from the patient himself, if the consciousness of the patients is clear; If not, it will be done near the patient. Patients will be divided into two groups using the clinical frailty scale (CFS) as frail if the score is ≥5 and non-fragile if the score is \<5. Demographic information and vaccination status (how many dose and type) will be questioned, SOFA score, APACHE II score will be recorded. Routine examinations made from the patient file; thorax computed tomography (CT) imaging, laboratory values, respiratory support information, drug treatments applied, patient positions will be recorded. Thoracic CT scans severity scores for each of the five lung lobes: 0 for no involvement (0%), 1 for minimal involvement (1%-25%), 2 for mild involvement (26-50%), 3 for moderate involvement (51%) -75) and 4 advanced involvement (76-100%). The total severity score will be the sum of the scores of the five lobes. If the score is ≤10, it will be considered as mild involvement, and if the score is \>10, it will be considered as severe involvement. Laboratory values; platelet and lymphocyte count, albumin, sodium, ferritin, D-dimer, crp, procalcitonin, interleukin-6 and glomerular filtration rate values, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, CRP/Albumin ratio, arterial blood gas will be recorded. Whether or not he received respiratory support; type (invasive/non-invasive positive pressure respiratory support or high-flow nasal oxygen therapy), duration will be recorded. The use and duration of vasoactive drugs administered, renal replacement therapy and its durations will be recorded. Patient positions will be recorded as supine, lateral decubitus, and prone. The length of stay in the intensive care unit and mortality of the patients will be recorded. Comparisons will be made between frail and non-fragile groups on all these evaluated parameters.
Interventions
DIAGNOSTIC_TESTPrognosis
survival/mortalite
Sponsors
Selcuk University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who over the age of 18 * Patients who diagnosed with Covid-19
Exclusion criteria
* Trauma patient * Pregnant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | 6 months | Mortality rate in the first 6 months after inyensive care unit admission |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Thorax computed tomography (CT) imaging | Within 2 weeks prior to admission ICU | Thoracic CT scans severity scores for each of the five lung lobes: 0 for no involvement (0%), 1 for minimal involvement (1%-25%), 2 for mild involvement (26-50%), 3 for moderate involvement (51%) -75) and 4 advanced involvement (76-100%). The total severity score will be the sum of the scores of the five lobes. If the score is ≤10, it will be considered as mild involvement, and if the score is \>10, it will be considered as severe involvement. |
| Laboratory values | Routine values at admission ICU | Platelet and lymphocyte count, albumin, sodium, ferritin, D-dimer, crp, procalcitonin, interleukin-6 and glomerular filtration rate values, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, CRP/Albumin ratio, arterial blood gas will be recorded |
| Respiratory support | As long as the patient stays in the intensive care unit | Type (invasive/non-invasive positive pressure respiratory support or high-flow nasal oxygen therapy), duration will be recorded |
| The Sequential Organ Failure Assessment Score, The Acute Physiology and Chronic Health Evaluation II Score | First 24 hours after admission intensive care unit | The Sequential Organ Failure Assessment score can range from a minimum of 0 to a maximum of 24 scores. Increasing scores are associated with increased hospital mortality. The Acute Physiology and Chronic Health Evaluation II Score can range from a minimum of 0 to a maximum of 71 scores. İncreasing scores are associated with increased hospital mortality. |
| Renal replacement therapy | Data will be collected from the admission to the intensive care unit up to 6 months or until mortality within this period. | Total time the patient used renal replacement therapy as long as he stayed in the intensive care unit |
| Patient positions | Data will be collected from the admission to the intensive care unit up to 6 months or until mortality within this period. | Patient positions will be recorded as supine, lateral decubitus, and prone. |
| Length of stay in the intensive care unit | Data will be collected from the admission to the intensive care unit up to 6 months or until mortality within this period. | The number of calendar days from the date of admission to the intensive care unit until discharge |
| Vasoactive drugs administered | Data will be collected from the admission to the intensive care unit up to 6 months or until mortality within this period. | Starting from the admission of patients to the intensive care unit, vasoactive drug records will be kept daily until either the patient's mortality in the intensive care unit or their discharge from the intensive care unit, up to a maximum of 6 months from admission to the intensive care unit. |
Countries
Turkey (Türkiye)
Outcome results
None listed